Compare BVFL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | NRXP |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.0M | 153.2M |
| IPO Year | 2023 | 2017 |
| Metric | BVFL | NRXP |
|---|---|---|
| Price | $21.64 | $3.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 7.4K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.19 | ★ 69.70 |
| EPS | ★ 0.55 | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | $39.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $1.65 |
| 52 Week High | $22.17 | $5.06 |
| Indicator | BVFL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 48.13 |
| Support Level | $20.27 | $3.45 |
| Resistance Level | $21.95 | $3.62 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 85.40 | 61.67 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. It operates in one segment commercial banking. The company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.